Compare PRDO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRDO | RAPP |
|---|---|---|
| Founded | 1994 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1997 | 2024 |
| Metric | PRDO | RAPP |
|---|---|---|
| Price | $32.77 | $39.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $42.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 524.5K | 290.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | 10.50 | ★ 24.34 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $581,296,000.00 | N/A |
| Revenue This Year | $4.28 | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $38.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.66 | $8.20 |
| 52 Week High | $38.50 | $42.27 |
| Indicator | PRDO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 61.52 |
| Support Level | $32.14 | $25.48 |
| Resistance Level | $32.79 | $41.33 |
| Average True Range (ATR) | 0.96 | 2.08 |
| MACD | -0.14 | 0.18 |
| Stochastic Oscillator | 2.31 | 84.38 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.